Coronavirus: Russia plans mass vaccination campaign in October

Henrietta Strickland
August 4, 2020

Immunogenicity or the amount of immune response generated by a vaccine is at the crux of this research.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals", the official said. "Following deliberation, it has recommended that permission be granted for phase 2 and 3 human clinical trials of the potential vaccine developed by the Oxford University - Covishield", an official source said. These include vaccines developed by the University of Oxford and AstraZeneca, Sinovac, the Wuhan Institute of Biological Products and Sinopharm, Beijing Institute of Biological Products and Sinopharm, Moderna, and the National Institutes of Health (NIH), and BioNTech and Pfizer.

Of the candidate vaccines, 26 groups are in clinical evaluation, and six are in the late and final stage of their trials. The revised proposal stated that as many as 1,600 people above the age of 18 years will come on board for the clinical trials in 17 select cities. "The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July to move into a Phase 3 trial in September", Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said.

Russian health authorities are preparing to start a mass vaccination campaign against coronavirus in October, the health minister has said.

Meanwhile, Russia is now developing a candidate vaccine.

It aims at mass-producing the vaccine, which will be priced below Rs 1,000.

The CDC also released a study that said COVID-19 had spread to almost half the staff and campers at a sleep-away camp in Georgia over a week and a half ago.

"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year", he said, adding that one developer is preparing production technology at three locations in central Russian Federation. "It is envisaged that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the purchase of 300 million doses, on behalf of all European Union member states", it said in a statement.

Other reports by Click Lancashire

Discuss This Article